Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz

Direkt zur Navigaton springen.
Direkt zum Inhalt springen.

Navigation/Suche

Publikationen

Suchbegriffe: EXPANDED DISABILITY STATUS SCALE, . Treffer: 35

2023

Buchmann, A; Pirpamer, L; Pinter, D; Voortman, M; Helmlinger, B; Pichler, A; Maceski, AM; Benkert, P; Bachmaier, G; Ropele, S; Reindl, M; Leppert, D; Kuhle, J; Enzinger, C; Khalil, M High serum neurofilament light chain levels correlate with brain atrophy and physical disability in multiple sclerosis.
Eur J Neurol. 2023; 30(5):1389-1399 Doi: 10.1111/ene.15742
Web of Science PubMed FullText FullText_MUG

Meier, S; Willemse, EAJ; Schaedelin, S; Oechtering, J; Lorscheider, J; Melie-Garcia, L; Cagol, A; Barakovic, M; Galbusera, R; Subramaniam, S; Barro, C; Abdelhak, A; Thebault, S; Achtnichts, L; Lalive, P; Müller, S; Pot, C; Salmen, A; Disanto, G; Zecca, C; D'Souza, M; Orleth, A; Khalil, M; Buchmann, A; Du, Pasquier, R; Yaldizli, Ö; Derfuss, T; Berger, K; Hermesdorf, M; Wiendl, H; Piehl, F; Battaglini, M; Fischer, U; Kappos, L; Gobbi, C; Granziera, C; Bridel, C; Leppert, D; Maleska, Maceski, A; Benkert, P; Kuhle, J Serum Glial Fibrillary Acidic Protein Compared With Neurofilament Light Chain as a Biomarker for Disease Progression in Multiple Sclerosis.
JAMA Neurol. 2023; 80(3):287-97 Doi: 10.1001/jamaneurol.2022.5250 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

Monschein, T; Dekany, S; Zrzavy, T; Ponleitner, M; Altmann, P; Bsteh, G; Kornek, B; Rommer, P; Enzinger, C; Di, Pauli, F; Kraus, J; Berger, T; Leutmezer, F; Guger, M, , Austrian, MS, Treatment, Registry, (AMSTR) Real-world use of natalizumab in Austria: data from the Austrian Multiple Sclerosis Treatment Registry (AMSTR).
J Neurol. 2023; Doi: 10.1007/s00415-023-11686-2
Web of Science PubMed FullText FullText_MUG

2022

Filippi, M; Preziosa, P; Meani, A; Dalla, Costa, G; Mesaros, S; Drulovic, J; Ivanovic, J; Rovira, A; Tintorè, M; Montalban, X; Ciccarelli, O; Brownlee, W; Miszkiel, K; Enzinger, C; Khalil, M; Barkhof, F; Strijbis, EMM; Frederiksen, JL; Cramer, SP; Fainardi, E; Amato, MP; Gasperini, C; Ruggieri, S; Martinelli, V; Comi, G; Rocca, MA, , MAGNIMS, Study, Group Performance of the 2017 and 2010 Revised McDonald Criteria in Predicting MS Diagnosis After a Clinically Isolated Syndrome: A MAGNIMS Study.
Neurology. 2022; 98(1):e1-e14 Doi: 10.1212/WNL.0000000000013016
Web of Science PubMed FullText FullText_MUG

Hechenberger, S; Helmlinger, B; Ropele, S; Pirpamer, L; Bachmaier, G; Damulina, A; Pichler, A; Khalil, M; Enzinger, C; Pinter, D Information processing speed as a prognostic marker of physical impairment and progression in patients with multiple sclerosis.
Mult Scler Relat Disord. 2022; 57: 103353 Doi: 10.1016/j.msard.2021.103353
Web of Science PubMed FullText FullText_MUG

Schoonheim, MM; Pinter, D; Prouskas, SE; Broeders, TA; Pirpamer, L; Khalil, M; Ropele, S; Uitdehaag, BM; Barkhof, F; Enzinger, C; Geurts, JJ Disability in multiple sclerosis is related to thalamic connectivity and cortical network atrophy.
Mult Scler. 2022; 28(1):61-70 Doi: 10.1177/13524585211008743
Web of Science PubMed FullText FullText_MUG

2021

Bsteh, G; Hegen, H; Altmann, P; Auer, M; Berek, K; Di Pauli, F; Leutmezer, F; Rommer, P; Wurth, S; Zinganell, A; Zrzavy, T; Deisenhammer, F; Berger, T Retinal layer thinning predicts treatment failure in relapsing multiple sclerosis.
Eur J Neurol. 2021; 19(4): Doi: 10.1111/ene.14829 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

Pinter, D; Khalil, M; Pirpamer, L; Damulina, A; Pichler, A; Fruhwirth, V; Ropele, S; Schmidt, R; Fuchs, S; Enzinger, C Long-term course and morphological MRI correlates of cognitive function in multiple sclerosis.
Mult Scler. 2021; 27(6):954-963 Doi: 10.1177/1352458520941474
Web of Science PubMed FullText FullText_MUG

2020

Aktas, O; Renner, A; Huss, A; Filser, M; Baetge, S; Stute, N; Gasis, M; Lepka, K; Goebels, N; Senel, M; Graf, J; Enzinger, C; Pinter, D; Antoch, G; Turowski, B; Hartung, HP; Albrecht, P; Otto, M; Tumani, H; Penner, IK Serum neurofilament light chain: No clear relation to cognition and neuropsychiatric symptoms in stable MS.
Neurol Neuroimmunol Neuroinflamm. 2020; 7(6): Doi: 10.1212/NXI.0000000000000885 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

Cole, JH; Raffel, J; Friede, T; Eshaghi, A; Brownlee, WJ; Chard, D; De Stefano, N; Enzinger, C; Pirpamer, L; Filippi, M; Gasperini, C; Rocca, MA; Rovira, A; Ruggieri, S; Sastre-Garriga, J; Stromillo, ML; Uitdehaag, BMJ; Vrenken, H; Barkhof, F; Nicholas, R; Ciccarelli, O; MAGNIMS study group Longitudinal Assessment of Multiple Sclerosis with the Brain-Age Paradigm.
Ann Neurol. 2020; 88(1):93-105 Doi: 10.1002/ana.25746 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

Guger, M; Traxler, G; Drabauer, M; Leitner-Pohn, D; Enzinger, C; Leutmezer, F; Oel, D; Di Pauli, F; Berger, T; Ransmayr, G Pregnancy Outcomes in Patients With Multiple Sclerosis Exposed to Natalizumab-A Retrospective Analysis From the Austrian Multiple Sclerosis Treatment Registry.
Front Neurol. 2020; 11(6):676-676 Doi: 10.3389/fneur.2020.00676 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

2019

Sinnecker, T; Clarke, MA; Meier, D; Enzinger, C; Calabrese, M; De Stefano, N; Pitiot, A; Giorgio, A; Schoonheim, MM; Paul, F; Pawlak, MA; Schmidt, R; Kappos, L; Montalban, X; Rovira, À; Evangelou, N; Wuerfel, J; MAGNIMS Study Group Evaluation of the Central Vein Sign as a Diagnostic Imaging Biomarker in Multiple Sclerosis.
JAMA Neurol. 2019; 130(11): Doi: 10.1001/jamaneurol.2019.2478 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

2018

Eshaghi, A; Marinescu, RV; Young, AL; Firth, NC; Prados, F; Jorge Cardoso, M; Tur, C; De Angelis, F; Cawley, N; Brownlee, WJ; De Stefano, N; Laura Stromillo, M; Battaglini, M; Ruggieri, S; Gasperini, C; Filippi, M; Rocca, MA; Rovira, A; Sastre-Garriga, J; Geurts, JJG; Vrenken, H; Wottschel, V; Leurs, CE; Uitdehaag, B; Pirpamer, L; Enzinger, C; Ourselin, S; Gandini Wheeler-Kingshott, CA; Chard, D; Thompson, AJ; Barkhof, F; Alexander, DC; Ciccarelli, O Progression of regional grey matter atrophy in multiple sclerosis.
Brain. 2018; 141(6):1665-1677 Doi: 10.1093/brain/awy088 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

Eshaghi, A; Prados, F; Brownlee, WJ; Altmann, DR; Tur, C; Cardoso, MJ; De Angelis, F; van de Pavert, SH; Cawley, N; De Stefano, N; Stromillo, ML; Battaglini, M; Ruggieri, S; Gasperini, C; Filippi, M; Rocca, MA; Rovira, A; Sastre-Garriga, J; Vrenken, H; Leurs, CE; Killestein, J; Pirpamer, L; Enzinger, C; Ourselin, S; Wheeler-Kingshott, CAMG; Chard, D; Thompson, AJ; Alexander, DC; Barkhof, F; Ciccarelli, O; MAGNIMS study group Deep gray matter volume loss drives disability worsening in multiple sclerosis.
Ann Neurol. 2018; 83(2):210-222 Doi: 10.1002/ana.25145 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

2017

Burgetova, A; Dusek, P; Vaneckova, M; Horakova, D; Langkammer, C; Krasensky, J; Sobisek, L; Matras, P; Masek, M; Seidl, Z Thalamic Iron Differentiates Primary-Progressive and Relapsing-Remitting Multiple Sclerosis.
AJNR Am J Neuroradiol. 2017; 38(6):1079-1086 Doi: 10.3174/ajnr.A5166 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

2013

Pichler, A; Enzinger, C; Fuchs, S; Plecko-Startinig, B; Gruber-Sedlmayr, U; Linortner, P; Langkammer, C; Khalil, M; Ebner, F; Ropele, S; Fazekas, F Differences and similarities in the evolution of morphologic brain abnormalities between paediatric and adult-onset multiple sclerosis.
Mult Scler. 2013; 19(2):167-172 Doi: 10.1177/1352458512448107
Web of Science PubMed FullText FullText_MUG

2011

Enzinger, C; Fuchs, S; Pichler, A; Wallner-Blazek, M; Khalil, M; Langkammer, C; Ropele, S; Fazekas, F Predicting the severity of relapsing-remitting MS: The contribution of cross-sectional and short-term follow-up MRI data.
Mult Scler. 2011; 17(6): 695-701. Doi: 10.1177/1352458510394454
Web of Science PubMed FullText FullText_MUG

Jehna, M; Langkammer, C; Wallner-Blazek, M; Neuper, C; Loitfelder, M; Ropele, S; Fuchs, S; Khalil, M; Pluta-Fuerst, A; Fazekas, F; Enzinger, C Cognitively preserved MS patients demonstrate functional differences in processing neutral and emotional faces.
Brain Imaging Behav. 2011; 5(4): 241-251. Doi: 10.1007/s11682-011-9128-1
Web of Science PubMed FullText FullText_MUG

2006

Burwick, RM; Ramsay, PP; Haines, JL; Hauser, SL; Oksenberg, JR; Pericak-Vance, MA; Schmidt, S; Compston, A; Sawcer, S; Cittadella, R; Savettieri, G; Quattrone, A; Polman, CH; Uitdehaag, BM; Zwemmer, JN; Hawkins, CP; Ollier, WE; Weatherby, S; Enzinger, C; Fazekas, F; Schmidt, H; Schmidt, R; Hillert, J; Masterman, T; Hogh, P; Niino, M; Kikuchi, S; Maciel, P; Santos, M; Rio, ME; Kwiecinski, H; Zakrzewska-Pniewska, B; Evangelou, N; Palace, J; Barcellos, LF APOE epsilon variation in multiple sclerosis susceptibility and disease severity: some answers.
NEUROLOGY. 2006; 66(9): 1373-1383. Doi: 10.1212/01.wnl.0000210531.19498.3f
Web of Science PubMed FullText FullText_MUG Google Scholar

Li, DK; Held, U; Petkau, J; Daumer, M; Barkhof, F; Fazekas, F; Frank, JA; Kappos, L; Miller, DH; Simon, JH; Wolinsky, JS; Filippi, M; Sylvia Lawry Centre for MS Research MRI T2 lesion burden in multiple sclerosis: a plateauing relationship with clinical disability.
NEUROLOGY. 2006; 66: 1384-1389. Doi: 10.1212/01.wnl.0000210506.00078.5c
Web of Science PubMed FullText FullText_MUG

2004

Hommes, OR; Sørensen, PS; Fazekas, F; Enriquez, MM; Koelmel, HW; Fernandez, O; Pozzilli, C; O'Connor, P Intravenous immunoglobulin in secondary progressive multiple sclerosis: randomised placebo-controlled trial.
Lancet. 2004; 364(9440):1149-1156 Doi: 10.1016/S0140-6736(04)17101-8
Web of Science PubMed FullText FullText_MUG Google Scholar

2003

Enzinger, C; Ropele, S; Strasser-Fuchs, S; Kapeller, P; Schmidt, H; Poltrum, B; Schmidt, R; Hartung, HP; Fazekas, F Lower levels of N-acetylaspartate in multiple sclerosis patients with the apolipoprotein E epsilon4 allele.
Arch Neurol. 2003; 60(1):65-70 Doi: 10.1001/archneur.60.1.65 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG Google Scholar

Niederwieser, G; Buchinger, W; Bonelli, RM; Berghold, A; Reisecker, F; Költringer, P; Archelos, JJ Prevalence of autoimmune thyroiditis and non-immune thyroid disease in multiple sclerosis.
J Neurol. 2003; 250(6):672-675 Doi: 10.1007/s00415-003-1053-9
Web of Science PubMed FullText FullText_MUG Google Scholar

2002

Kapeller, P; Brex, PA; Chard, D; Dalton, C; Griffin, CM; McLean, MA; Parker, GJ; Thompson, AJ; Miller, DH Quantitative 1H MRS imaging 14 years after presenting with a clinically isolated syndrome suggestive of multiple sclerosis.
Mult Scler. 2002; 8(3):207-210 Doi: 10.1191%2F1352458502ms822oa
Web of Science PubMed FullText FullText_MUG

Sorensen, PS; Fazekas, F; Lee, M Intravenous immunoglobulin G for the treatment of relapsing-remitting multiple sclerosis: a meta-analysis.
Eur J Neurol. 2002; 9(6):557-563 Doi: 10.1046%2Fj.1468-1331.2002.00501.x
Web of Science PubMed FullText FullText_MUG

2001

Balássy, C; Bernert, G; Wöber-Bingöl, C; Csapó, B; Kornek, B; Széles, J; Fleischmann, D; Prayer, D Long-term MRI observations of childhood-onset relapsing-remitting multiple sclerosis.
Neuropediatrics. 2001; 32(1):28-37 Doi: 10.1055/s-2001-12219
Web of Science PubMed FullText FullText_MUG

1999

Zimmermann, C; Walther, EU; Goebels, N; Lienert, C; Kappos, L; Hartung, HP; Hohlfeld, R Interferon beta-1b for treatment of secondary chronic progressive multiple sclerosis
Nervenarzt. 1999; 70(8):759-763 Doi: 10.1007/s001150050508
Web of Science PubMed FullText FullText_MUG

1998

Ebers, GC; Rice, G; Lesaux, J; Paty, D; Oger, J; Li DKB, Beall S, Devonshire V, Hashimoto S, Hooge J, Kastrukoff L, Krieger C, Mezei M, Seland P, Vorobeychi G, Morrison W, Nelson J, Freedman MS, Chrisie S, Nelson R, Rabinovitch H, Freedman C, Hartung HP, Rieckmann P, Archelos J, Jung S, Weilbach F, Flachenecke P, Sauer J, Hommes O, Jongen P, Brouwer S, McLeod J, Pollard J, Ng R, Sandberg-Wollheim M, Kallen K, Nilsson P, Ekberg R, Lundgren A, Jadback G, Wikstrom J, Multanen J, Valjakka M, Carton H, Lissoir F, Declerq I, Vieren M, Peeters E, Dubois B, Dekeersmaeker E, Van Herle A, Hughes RAC, Sharrack B, Soudain S, Panelius M, Eralinna J, Soilu-Hanninen M, Murto S, Medaer R, Broeckx J, Vanroose E, Bogaers A, Blumhardt LD, Edwards S, Liu C, Orpe V, Barnes D, Schwartz M, Stoy N, Harraghy C, Bertelsmann F, Uitdehaag B, Nasseri K, Chofflon M, Roth S, Kappos L, Huber S, Bellaiche Y, Senn C, King J, Jubert J, Whitten S, Newsom-Davis JM, Palace J, Lee M, Evangelou N, Pinto A, Cavey A, Sindic CJM, Monteyne P, Verougstraete D, Van Doorn PA, Moll W, Visser L, Willems M, Martina I, Buljevac D, Loman L, Bates D, Pandit D, Irving J, Rhodes B, Riddehough A, Zhao GJ, Wang X, Cheng Y, Ammoury N, Dupont F, Galazka A, Hyde R, Olson M, Pernin MO, Abdul-Ahad AK, Hommes O, Noseworthy J, Borden E, O'Brien P, Wolinsky J Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group.
LANCET. 1998; 352(9139): 1498-1504. Doi: 10.1016/S0140-6736(98)03334-0
Web of Science PubMed FullText FullText_MUG

Kappos, L; Polman, C; Pozzilli, C; Thompson, A; Dahlke, F; Knight R, Hern J, Coleman R, Gerrie L, Cooper G, Moore J, Boringa J, van Oosten B, Ronner H, Schrijver H, Truyen L, Montalban J, Rio J, Tintore M, Jacas C, Marzo E, Lechner-Scott J, Huber S, Lienert C, Brunnschweiler H, Hawkins S, Droogan A, McDonnell G, Duddy M, McKinstry S, Altenkirch H, Baum K, Einhaupl K, Marx P, Poewe W, Walter G, Akman H, Brockmeier B, Scherer P, Zschenderlein R, Schmierer K, Gelderblom H, Hartmann A, Stapf C, Luschow A, Mackert B, Schumacher H, Masuhr F, Hempel T, Zimmermann R, Munch M, Francis D, Heafield M, Al-Memar A, Winer J, Chong M, Brochet B, Gayou A, Auriacombe S, Dousset V, Wiles C, Thomas F, Pickersgill T, Hinds N, Dawson K, Hughes T, Hutchinson M, Murphy R, Redmond J, Webb S, Stoll G, Jander S, Hagemann G, Koller H, Hanemann C, Kolmel H, Reichel D, Petereit K, Thieme A, Khatami A, Neumann M, Amaducci L, Massacesi L, Siracusa G, Amato M, Bartolozzi L, Repice A, Minderhoud J, De Keyser J, Zorgdrager A, Zwanikken C, Poser S, Polak T, Gunther A, Bitsch A, Borner T, Weber F, Wikstrom J, Farkkila M, Majuri H, Sumelahti M, Telakivi T, Fredrikson S, Martin C, Miller D, O'Riordan J, Brex P, Kapoor R, Werring D, Confavreux C, Brunet P, Hannoun D, Brudon F, Moreau T, Blanc S, D'Hooghe M, Jacobs K, Lissoir F, Demonty L, Comi G, Colombo B, Rossi P, Rodegher M, Santuccio G, Martinelli F, Hohlfeld R, Walther E, Goebels N, Dang T, Lindert R, Voltz R, Cartlidge N, Bates D, Moran G, Pandit L, Westwood M, Haller P, Sommer J, Bitter J, Suss F, Mellies J, Mucha P, Lyon-Caen O, Degos JD, Roullet E, Lubetzki C, Creange A, Tourbah A, Pez D, Lecanuet P, Nicolt P, Edan G, Belliard S, De Marco O, Cahagne V, De Burghgraeve V, Brunet I, Fieschi C, Millefiorini E, Gasperini C, Buttinelli C, Frontini M, Howell S, Hadjivassiliou M, Gibson A, Graham A, Harkness K, Lawden M, Clanet M, Wauban E, Azais-Vuillemin C, Lau GKK, Louis C, Panelius M, Ruutiainen J, Eralinna J, Soilu-Hanninen M, Gold R, Hartung HP, Jung S, Bayas A, Flachenecker P, Weilbach F, Archelos J, Kollegger H, Vass K, Asenbaum S, Chatsakos T, Beckmann K, Ghazi M, Wagner K, Miltenburger C, McFarland H, Petkau J, Sabouraud O, Toyka K Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. European Study Group on interferon beta-1b in secondary progressive MS.
LANCET. 1998; 352(9139): 1491-1497. Doi: 10.1016/S0140-6736(98)10039-9
Web of Science PubMed FullText FullText_MUG

1997

Fazekas, F; Deisenhammer, F; Strasser-Fuchs, S; Nahler, G; Mamoli, B Randomised placebo-controlled trial of monthly intravenous immunoglobulin therapy in relapsing-remitting multiple sclerosis. Austrian Immunoglobulin in Multiple Sclerosis Study Group.
Lancet. 1997; 349(9052):589-593 Doi: 10.1016/S0140-6736(96)09377-4
Web of Science PubMed FullText FullText_MUG Google Scholar

↑ Seitenanfang / Navigation